Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Hereditary Breast/Ovarian Cancer - BRCA1|Hereditary Breast/Ovarian Cancer - BRCA2|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer
Interventions: DRUG: veliparib|DRUG: cisplatin|DRUG: vinorelbine tartrate|OTHER: laboratory biomarker analysis|OTHER: pharmacological study
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)